Frost & Sullivan Independent Equity Research
BiolineRx: Continued advancement and execution of BiolineRx’s lead oncology project – BL-8040; sufficient funds to support clinical strategy; stock target price remains at NIS 5.15
![bioline bioline](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/bioline-nx7oepmjwr0nqu046yc3t5fs9jyo1sg30b9j97eohk.png)
Company: BioLineRx
Sector: Pharmaceuticals
Report type: 2017 Annual Report
For all past reports click here
Published on: 20 March, 2018